immediate-early promoter-enhancer, and the long terminal repeat promoters of Rous sarcoma virus, human immunodeficiency virus type 1, and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression vector and plasmids containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. Expression of wild-type p53 correlated with a consistent and significant (6-to 76-fold) reduction of reporter enzyme activity. A mutation at amino acid 143 of p53 releases this inhibition significantly with all the promoters studied. Expression of a p53 mutated at any one of the five amino acid positions 143, 175, 248, 273, and 281 also correlated with a much smaller (one-to sixfold) reduction of reporter enzyme activity from the herpes simplex virus type 1 thymidine kinase promoter.
These mutant forms of p53 are found in various cancer cells. Thus, failure of tumor suppression correlates with loss of the promoter inhibitory effect of p53.
p53 is a nuclear phosphoprotein that was initially detected in association with simian virus 40 (SV40) large T antigen in virus-transformed rodent cells (31, 33) . Elevated levels of p53 were subsequently observed in cell lines transformed by a variety of agents, including DNA and RNA tumor viruses, irradiation, and chemical carcinogens (13, 16, 24, 29, 35, 48) . When genomic and cDNA clones of p53 were found to immortalize primary cells and to cooperate with the ras oncogene in transformation of primary cells, p53 was consigned to the nuclear oncogene family of myc and myb (16, 29, 45) ; only recently has it been learned that the original clones contained activating mutations (24) . Expression of wild-type p53 has now been shown to inhibit proliferation of transformed cells, suppress oncogene-mediated cell transformation, and eliminate the tumorigenic potential of tumorderived cell lines (2, 3, 8, 9, 14-16, 18, 36, 38, 40) . Like the retinoblastoma susceptibility (RB) gene, p53 is now considered to be an antioncogene or tumor suppressor gene (see reference 32 for a review). Somatic and germ line (in Li-Fraumeni syndrome) mutation of the p53 gene has been detected in a variety of human tumors, with mutations concentrated in phylogenetically conserved sequence domains (26, 32, 34, 54) . At present, p53 mutations are the most frequently reported genetic defects in human cancer (3, 26, 27, 44, 56, 58) .
Several biochemical functions are attributed to p53. p53-GAL4 fusion proteins can activate transcription from promoters containing GAL4-binding sites, suggesting that p53 is a transactivator (17, 47) . Moreover, sequence-specific DNA binding by p53 has been reported (4, 30) . Wild-type (but not mutant) p53 binds to the 21-bp repeats of the SV40 early and late promoters (4) and to TGCCT repeats present in the human ribosomal gene cluster (30) . p53 inhibits SV40 DNA replication in vivo and in vitro by complexing with T antigen * Corresponding author. and inhibiting the unwinding capability of T antigen (5, 19, 20, 59) . Wild-type p53 has recently been shown to inhibit c-fos transcription (21) and to repress transcription from several cellular promoters (10, 21, 50) .
The human proliferating-cell nuclear antigen (PCNA) gene is growth regulated (1, 28) and encodes a protein that is a component of the DNA replication machinery of the cell. PCNA has been identified as a cofactor of DNA polymerase 8 (6, 46, 55) . Mercer et al. (39) demonstrated a downregulation of PCNA mRNA and protein by wild-type p53. However, the mechanism of this regulation was not known since the possibility that p53 might affect the PCNA promoter activity was not examined.
Several viruses have mechanisms to target (and presumably inactivate) wild-type p53 by their transforming proteins. SV40 large T antigen, adenovirus 5 E1B, and E6 of human papillomavirus (HPV) types 16 and 18 bind specifically to p53 and either sequester it (large T, E1B) or promote its degradation (E6) (31, 33, 51, 52, 60) . The effect of p53 on promoter activity of viruses has not been investigated in detail.
We studied the effect of wild-type and mutant human p53 expression on the activity of PCNA and several viral promoters fused to a chloramphenicol acetyltransferase (CAT) reporter gene. Expression of wild-type p53 correlated with a consistent and significant (6- Cell culture and transfection. Human cervical carcinoma (HeLa) and monkey kidney (Vero) cells were obtained from the American Type Culture Collection and propagated in minimum essential medium containing 10% fetal calf serum and Dulbecco's minimum essential medium, respectively. Subconfluent cells were transfected by the calcium phosphate-DNA coprecipitation method with a dimethyl sulfoxide shock 4 h posttransfection (8, 23) . In a typical experiment, S x 10 cells were cotransfected with 2.5 ,ug of a reporter gene construct and 5 ,ug of a p53 expression plasmid (or 5 ,ug of the expression vector without p53 sequences as a control). All transfection experiments were repeated several times.
CAT assay. Cells were harvested 48 h posttransfection and lysed by three successive cycles of freezing and thawing. Extracts were normalized for protein concentration and assayed for CAT enzyme activity (22) . CAT activity was detected by thin-layer chromatographic separation of ['4C]chloramphenicol from its acetylated derivatives and quantitated by cutting out radioactive spots from the thinlayer chromatograph plate after autoradiography. 70 ,iCi/ml in methionine-free minimal essential medium (49) . Cells were lysed, and extract aliquots were immunoprecipitated with PAb421, a cross-species, carboxy-terminal-specific, anti-p53 monoclonal antibody (p53 Ab-1; Oncogene Science) (57) , and protein A-agarose (Calbiochem). Immunoprecipitated proteins were separated by sodium dodecyl RESULTS Expression of wild-type and mutant human p53 proteins in transfected HeLa cells. We used wild-type and mutant human p53-expressing clones for our analysis of the effect(s) of p53 on the function of various promoters. The mutants were c143A, 175H, c248W, 273H, and 281G, where capital letters indicate mutant amino acids and small c indicates cDNA clones. These mutants were chosen because they contain the frequently mutated amino acid residues found in tumors (26) (Fig. 1) . These residues fall in or near four domains (II to V) which are highly conserved in vertebrate species (54) .
To (Fig. 3) . Thus, the promoter inhibition is due to wild-type p53, and a mutation in the p53 gene destroys the inhibitory effect.
Effect of expression of wild-type and mutant p53 on various viral promoters. To analyze the effect of expression of wild-type and mutant p53 on various viral promoters, we used the following promoter-CAT constructs: SV40 early promoter (pSV2.CAT) (22) , CMV early promoter-enhancer (CMV.CAT) (11) , HSV-1 UL9 promoter (UL9.CAT) (13a), HIV-1 LTR (HIV.CAT) (43), RSV LTR (RSV.CAT) (12) , and HTLV-I LTR (HTLV.CAT) (53) . The promoter activities were determined by CAT assay after cotransfecting the respective promoter constructs with the pHCMV.Bam expression vector alone or with the plasmid expressing either the wild-type or a mutant (c143A) form of p53 into HeLa cells ( Fig.  4 ; Table 1 ). The experiments were repeated several times with qualitatively similar results. Representative examples are shown in Fig. 4 Fig. 3. For pSV2 .CAT, 0.5 p,g of the CAT plasmid was used with S pLg of vector or p53 expression plasmid. All others were used as described in Materials and Methods. by the expression of wild-type p53. On the other hand, the mutant p53 had a relatively minor, if any, effect on expression of the various promoter-CAT constructs. In most of the cases, although the inhibition persisted with the mutant p53 (c143A), its extent was greatly reduced. In at least one case (HTLV-.CAT), the mutant actually stimulated the activity about 50%. This is not entirely surprising since recently Chin et al. (10) reported that the human multi-drug-resistant (MDR1) gene promoter is activated by another mutant p53 (175H).
All the promoters examined were inhibited by wild-type human p53, albeit to different extents. SV40 early promoter seems to be least affected under our assay conditions. To observe a significant extent of inhibition, we had to lower the pSV2.CAT concentration to 0.5 pLg per transfection. The difference in the extent of inhibition by the same amount of wild-type p53 expression construct indicates that the observed promoter inhibition is possibly not that all the mutants tested show a dramatic loss in mediating inhibition of the promoter. The failure of tumor suppression by these mutant p53 proteins correlates with the loss of the promoter inhibitory effect.
Inhibition of activity of various promoters by wild-type human p53 in Vero cells. To determine whether the p53-mediated promoter inhibition is cell type specific or is influenced by the expression of E6 of HPV 18 in the HeLa cell line, we chose also to use a monkey kidney cell line (Vero). Table 2 shows the percentage of acetylation of [14C]chloramphenicol with various promoters in the presence and absence of wild-type human p53. The results indicate that in the Vero cell line (a nontransformed cell line) also, wild-type human p53 significantly inhibits various promoter activities (6-to 28-fold).
DISCUSSION
The results described above show that overexpression of wild-type human p53 can exert an inhibitory effect on a variety of viral promoters as well as on the cellular PCNA promoter (6-to 76-fold, Table 1 ). Several other groups recently reported an inhibitory activity of p53 on different cellular promoters. Santhanam et al. (50) found that wildtype p53 inhibited the promoters for interleukin 6, c-fos, beta-actin, and the porcine major histocompatibility complex class I gene. Ginsberg et al. (21) described the inhibition of c-fos, beta-actin, p53, hsc7O, and c-jun promoters, while Chin et al. (10) showed that the MDR1 gene promoter was inhibited by p53. Combining our results with those reported previously, it becomes clear that a wide variety of cellular and viral promoters are inhibited by wild-type human p53. In all the cases, mutant p53 proteins found in tumors were either less inhibitory or in some cases stimulatory (10) Table 2 ). This suggests that the promoter inhibition is probably because of p53 alone.
Because p53 possesses the promoter inhibitory activity, it is possible that at least one of the mechanisms by which wild-type p53 inhibits cellular proliferation is by inhibiting cellular promoters. This is based on the assumption that p53 directly inhibits transcriptional activity. This remains to be determined by using in vitro transcription systems. However, the fact that the inhibitory effect of p53 is exerted on a wide variety of promoters, both cellular and viral, suggests that p53 probably affects one or more of the common generalized transcription factors or that it binds to promoter sequences nonspecifically and inhibits transcription. At (30) as well as the SV40 early promoter region (4). It has also been shown that it can function as a transcriptional activator when expressed as a chimera with the GALA DNA-binding domain on promoters with GAL4 DNA-binding sites (17, 47) . The same molecule may function as an activator as well as an inhibitor of transcription. It is tempting to speculate that while p53 acts as a generalized inhibitor of transcription, it could activate certain promoters where it can bind effectively. We have observed that it requires a relatively higher concentration of p53 plasmid to inhibit the SV40 early promoter, which has p53-binding sites (4) . One can speculate that p53 may exert its tumor suppressor function in several ways. First, under certain conditions, p53 may inhibit genes required for progression through the cell cycle. The inhibition of the PCNA promoter demonstrated in this study supports this mechanism. In addition, p53 may also activate expression of genes involved in the regulation of normal cell cycle progression. This regulation of expression may require the presence of p53-binding sites as cis-acting factors at the target gene. A possibility also exists that p53 activates the production of a factor that interacts with the transcription machinery and inhibits gene expression. Thus, p53 may act as a central factor in controlling the dynamic pattern of gene expression required for maintenance of a normal cell cycle. Both the tumor suppressor gene products RB and p53 have cellular antiproliferative activity. In one way, at least, they have a similar biochemical function-inhibition of transcription. It has been suggested that at least one mechanism by which RB may inhibit specific transcriptional activity is by complexing with the transcription factor E2F (7, 42) . While it is not yet clear how p53 exerts its effect, similarity in biochemical function is an intriguing common theme.
